Celldex Therapeutics 15min Chart Indicates Overbought RSI, KDJ Death Cross Detected.

Celldex Therapeutics' 15-minute chart has reached an overbought RSI level and is exhibiting a death cross on the KDJ indicator, as of August 12, 2025 at 12:45. This suggests that the stock price has experienced a significant and rapid increase, potentially exceeding its fundamental support. The momentum of the stock price is shifting towards the downside, and it has the potential to continue decreasing further.

As of August 12, 2025, at 12:45, Celldex Therapeutics (CLDX) stock has reached an overbought Relative Strength Index (RSI) level and exhibited a death cross on the KDJ indicator. These technical signals suggest a significant and rapid increase in the stock price, potentially exceeding its fundamental support. The momentum of the stock price is shifting towards the downside, indicating a potential for further declines.

The RSI level above 70 is considered overbought, signaling that the stock may be overvalued and due for a correction. The death cross on the KDJ indicator, where the Stochastic %K line crosses below the %D line, further indicates a bearish signal. This combination of indicators suggests that the stock price could experience a significant downturn.

Celldex Therapeutics has been making notable progress in its clinical trials, particularly with its lead drug, barzolvolimab, which has shown promising results in Phase 2 studies for chronic urticaria. However, the technical indicators currently point to a potential downtrend in the stock price, which investors should be aware of.

Investors should monitor the upcoming data presentations at the EAACI Congress 2025 in Glasgow, scheduled for June 12th and 14th, to gauge the impact of the company's clinical trial results on the stock price. The presentations will feature notable experts and provide insights into the long-term efficacy and tolerability of barzolvolimab.

References:
[1] https://www.stocktitan.net/news/CLDX/
[2] https://www.stocktitan.net/news/CLDX/